No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
EXAS240517C35000
- 24.90
- 0.000.00%
15min DelayClose Apr 29 10:30 ET
0.00High0.00Low
24.90Open24.90Pre Close0 Volume2 Open Interest35.00Strike Price0.00Turnover210.47%IV0.71%PremiumMay 17, 2024Expiry Date24.48Intrinsic Value100Multiplier9DDays to Expiry0.42Time Value100Contract SizeAmericanOptions Type0.9596Delta0.0043Gamma2.39Leverage Ratio-0.0939Theta0.0083Rho2.29Eff Leverage0.0083Vega
Intraday
- 5D
- 1D
News
Express News | Exact Sciences Corp Shares Down 9.4% After the Bell Following Results, Guidance
Express News | Exact Sciences Corp - Maintains Full-Year 2024 Revenue and Adjusted Ebitda Guidance
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersCytomX Therapeutics (NASDAQ:CTMX) stock increased by 87.1% to $7.84 during Wednesday's after-market session. The market value of their outstanding shares is at $534.1 million. As per the press
Earnings Flash (EXAS) EXACT SCIENCES Reports Q1 Revenue $637.5M, Vs. Street Est of $626.8M
04:25 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (EXAS) EXACT SCIENCES Reports Q1 Revenue $637.5M, vs. Street Est of $626.8M
Express News | Exact Sciences Shares Are Trading Lower After the Company Reported Mixed Q1 Financial Results
Exact Sciences Shares Are Trading Lower After the Company Reported Mixed Q1 Financial Results.
Exact Sciences Shares Are Trading Lower After the Company Reported Mixed Q1 Financial Results.
Comments
Exact Sciences' progress has failed to meet high market expectations, yet its consistent revenue growth suggests it may be worth further investigation. The company's performance has underperformed the broader market, which gained around 31%.
2
The company's strained balance sheet and lack of EBIT level profitability heighten risk. Its debt management and growth rate are key concerns, with faster growth expected from unprofitable firms.
Exact Sciences' low P/S ratio is due to its poor revenue outlook. Investors foresee limited growth, thus are only willing to pay less for the stock, making a strong share price rise unlikely.
Exact Sciences' growth rate is somewhat slow, showing a 20% rise in revenue while lacking profitability at an EBIT level. Considerable liabilities and negative EBIT results make its financial status seem precarious and risky.
Read more